Detail of "170105-16-5"

Reference

Design, synthesis and antimuscarinic activity of a series of 4-(1-imidazolyl)-2,2-diphenylbutanamides: Discovery of potent and subtype-selective antimuscarinic agents

Design, synthesis and antimuscarinic activity of a series of 4-(1-imidazolyl)-2,2-diphenylbutanamides: Discovery of potent and subtype-selective antimuscarinic agents. Miyachi, Hiroyuki; Segawa, Mitsuru (Discovery Research Laboratories, Kyorin Pharmaceutical Co., Ltd., Tochigi 329-0114, Japan). Current Topics in Medicinal Chemistry (Trivandrum, India), 3, 153-163 (English) 2003 Research Trends. CODEN: CTMCFO. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) As part of our program directed toward the development of new, selective agents with potential utility in the treatment of urinary incontinence assocd. with bladder muscle instability, a series of 4-(1-imidazolyl)-2,2-diphenylbutanamide derivs. were examd. for M1, M2, and M3 muscarinic receptor subtype selectivity in isolated tissue assays. The compds. that showed potency and/or selectivity in these tests were further evaluated for in vivo antimuscarinic effects on various organs and tissues, including urinary bladder, salivary gland, and eye in rats. The structure-activity relationships of 4-(1-imidazolyl)-2,2-diphenylbutanamide derivs. and related compds.Some chemicals with cas registry numbers like 170105-16-5 are also used. are also discussed. This study led to the identification of a novel dual antagonist of M1 and M3 muscarinic receptors, 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutanamide (KRP-197/ONO-8025), as a candidate drug for the treatment of urinary bladder dysfunction. 170105-16-5 is just another one chemical used in this study. ..

Design, synthesis and antimuscarinic activity of a series of 4-(1-imidazolyl)-2,2-diphenylbutanamides: Discovery of potent and subtype-selective antimuscarinic agents

Design, synthesis and antimuscarinic activity of a series of 4-(1-imidazolyl)-2,2-diphenylbutanamides: Discovery of potent and subtype-selective antimuscarinic agents. Miyachi, Hiroyuki; Segawa, Mitsuru (Discovery Research Laboratories, Kyorin Pharmaceutical Co., Ltd., Tochigi 329-0114, Japan). Current Topics in Medicinal Chemistry (Trivandrum, India), 3, 153-163 (English) 2003 Research Trends. CODEN: CTMCFO. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) As part of our program directed toward the development of new, selective agents with potential utility in the treatment of urinary incontinence assocd. with bladder muscle instability, a series of 4-(1-imidazolyl)-2,2-diphenylbutanamide derivs. were examd. for M1, M2, and M3 muscarinic receptor subtype selectivity in isolated tissue assays. The compds. that showed potency and/or selectivity in these tests were further evaluated for in vivo antimuscarinic effects on various organs and tissues, including urinary bladder, salivary gland, and eye in rats. The structure-activity relationships of 4-(1-imidazolyl)-2,2-diphenylbutanamide derivs. and related compds.Some chemicals with cas registry numbers like 170105-16-5 are also used. are also discussed. This study led to the identification of a novel dual antagonist of M1 and M3 muscarinic receptors, 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutanamide (KRP-197/ONO-8025), as a candidate drug for the treatment of urinary bladder dysfunction. 170105-16-5 is just another one chemical used in this study. ..